Bluefin Capital Management, LLC Uni Qure N.V. Transaction History

Bluefin Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.7 - $23.07 $1.03 Million - $1.27 Million	-55,073 Reduced 69.49%	24,178 $486,000
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $206,024 - $310,628	11,370 Added 16.75%	79,251 $1.8 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $266,399 - $400,697	15,689 Added 30.06%	67,881 $1.27 Million
Q2 2022 Aug 15, 2022	SELL	$13.15 - $20.45 $30,652 - $47,668	-2,331 Reduced 4.28%	52,192 $964,000
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $792,764 - $1.17 Million	54,523 New	54,523 $985,000
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $293,581 - $522,325	-14,505 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $412,414 - $606,016	-15,856 Reduced 52.22%	14,505 $464,000
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $11,988 - $14,868	-400 Reduced 1.3%	30,361 $935,000
Q1 2021 May 17, 2021	SELL	$29.24 - $42.03 $839,363 - $1.21 Million	-28,706 Reduced 48.27%	30,761 $1.04 Million
Q4 2020 Feb 10, 2021	SELL	$35.35 - $50.67 $1.31 Million - $1.88 Million	-37,112 Reduced 38.43%	59,467 $2.15 Million
Q3 2020 Nov 16, 2020	BUY	$35.98 - $47.66 $3.47 Million - $4.6 Million	96,579 New	96,579 $3.56 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Bluefin Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bluefin Capital Management, LLC with notifications on news.